Oxford have have a way to treat autoimmune disorders and decrease adverse effects of treatment. The findings appear in Science Translational Medicine.
An autoimmune disorder is a condition that occurs when the immune system mistakenly attacks a normal body part. Overall, autoimmune diseases are common, affecting a large number of people worldwide. Common autoimmune diseases include type 1 diabetes, systemic lupus erythematosus, and inflammatory bowel disease. Currently, there are a variety of treatment options for autoimmune diseases. But these treatments may compromise the patients' immune system, making them vulnerable to other opportunistic illnesses. So there is an need to develop novel treatments that cause less side effects.
A team of scientists led by Prof. Lars Fugger from University of Oxford aimed to find a new way decrease the side effects of treatment for autoimmune diseases. They mainly focused on a gene called TYK2 because genetic variants in this gene had been shown to influence autoimmune diseases. The TYK2 gene provides instructions for making a protein that helps fight infection and cancer. However, this protein can also contribute to autoimmune disorders. CusAb offers Recombinant Itgb5
By performing genetic meta-analysis, Fugger's team found that a single genetic variant in TYK2 significantly protects against autoimmunity. The genetic variant leads to a change in the TYK2 protein, which decreases the function of the protein and inhibits the activity of immune cells. On the other hand, the protective TYK2 genetic variant also prevents immunodeficiency. People with this genetic variant were no more likely to develop cancer and other severe disorders, said Prof. Fugger. In sum, the data suggested that TYK2 could serve as a potential drug target for autoimmune diseases.
留言列表
